Cognition Therapeutics, Inc. announced positive results from its Phase 2 trials of zervimesine (CT1812) in treating dementia with Lewy bodies (DLB) and Alzheimer’s disease, indicating significant ...
Cognition Therapeutics announces promising Phase 2 trial results for CT1812 in dementia with Lewy bodies, with plans for late-stage trials. Cognition Therapeutics, Inc. announced promising topline ...
While Alzheimer's disease is the most common type of dementia, there's another variation that is also relatively prevalent. Lewy body dementia (LBD) affects more than 1 million people in the US. It is ...
Cognitive profiles for early diagnosis of Dementia with Lewy bodies (DLB) have been outlined in a new study. Although DLB is the second most common neurodegenerative dementia following Alzheimer's ...
• On track to report topline data from the Phase 2b trial in December 2024 • Neflamapimod has the potential to restore function and improve cognitive and motor functions in DLB patients • 96% of ...
"Every day there’s new grief," says a caretaker in PEOPLE's exclusive clip from the documentary 'Facing the Wind' The heartbreaking toll of dementia is explored in a new documentary, Facing the Wind, ...
September 4, 2025 -- A team of researchers found there is a possible molecular connection between air pollution and an increased risk of developing Lewy body dementia. The study builds on a decade of ...
TipRanks on MSN
CervoMed Reports Q3 2025 Financial Results and Progress
Cervomed Inc. ( ($CRVO) ) has released its Q3 earnings. Here is a breakdown of the information Cervomed Inc. presented to its investors. CervoMed ...
• 96% of patients enrolled in RewinD-LB completed the 16-week portion of the study, of which 98% continued into the open label extension BOSTON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback